Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has started a Phase I, dose-escalation study for its selective kinase inhibitor, ENMD-2076, in advanced cancer patients.
Subscribe to our email newsletter
The Phase I study will assess safety and tolerability of orally administered ENMD-2076 in refractory cancer patients. In addition, pharmacokinetics will be assessed to determine a dose-dependent response to treatment with ENMD-2076. Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigator for the study.
The administration of ENMD-2076 to the first patient in this important Phase I study will also trigger a milestone payment by EntreMed pursuant to EntreMed’s acquisition of Miikana Therapeutics. Under the terms of the merger agreement with Miikana, the dosing of the first patient triggers a $2 million payment to the former Miikana stockholders, either in cash or shares of EntreMed common stock.
James Burns, EntreMed’s president and CEO, said: “ENMD-2076 is an exciting selective kinase inhibitor with potent single agent activity that has induced tumor regression in multiple preclinical models. In parallel with the clinical trial, we will seek a pharmaceutical or biotech partner to help accelerate the development of our novel selective kinase inhibitor.”